Literature DB >> 15864274

Cannabinoid-based drugs as anti-inflammatory therapeutics.

Thomas W Klein1.   

Abstract

In the nineteenth century, marijuana was prescribed by physicians for maladies ranging from eating disorders to rabies. However, as newer, more effective drugs were discovered and as the potential for abuse of marijuana was recognized, its use as a therapeutic became restricted, and only recently has its therapeutic potential been re-evaluated. Recent studies in animal models and in humans have produced promising results for the treatment of various disorders - such as obesity, cancer, and spasticity and tremor due to neuropathology - with drugs based on marijuana-derived cannabinoids. Moreover, as I discuss here, a wealth of information also indicates that these drugs have immunosuppressive and anti-inflammatory properties; therefore, on the basis of this mode of action, the therapeutic usefulness of these drugs in chronic inflammatory diseases is now being reassessed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864274     DOI: 10.1038/nri1602

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  231 in total

1.  Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator.

Authors:  X Zhang; Y Maor; J F Wang; G Kunos; J E Groopman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

3.  Combined effects of HIV and marijuana use on neurocognitive functioning and immune status.

Authors:  April D Thames; Zanjbeel Mahmood; Alison C Burggren; Ahoo Karimian; Taylor P Kuhn
Journal:  AIDS Care       Date:  2015-12-23

4.  Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-30       Impact factor: 4.219

Review 5.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

6.  Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.

Authors:  Sarah Moretti; Silvia Franchi; Mara Castelli; Giada Amodeo; Lorenzo Somaini; Alberto Panerai; Paola Sacerdote
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-10       Impact factor: 4.147

7.  CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Authors:  M Rajesh; P Mukhopadhyay; G Haskó; J W Huffman; K Mackie; P Pacher
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

8.  Beneficial Effects of Cannabis on Blood-Brain Barrier Function in Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Scott Peterson; Mariana Cherner; Erin Morgan; Rachel Schrier; Bin Tang; Martin Hoenigl; Scott Letendre; Jenny Iudicello
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

9.  Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats.

Authors:  Mutsumi Fujii; Prativa Sherchan; Paul R Krafft; William B Rolland; Yoshiteru Soejima; John H Zhang
Journal:  J Neurol Sci       Date:  2014-04-30       Impact factor: 3.181

Review 10.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.